We are live on ! Find out more
TPC

Takeda Pharmaceutical Company Portfolio holdings

AUM $16.4M
1-Year Est. Return 195.92%
This Fund
S&P 500
This Quarter Est. Return
-3.47%
1 Year Est. Return
+195.92%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$232M
AUM Growth
-$56.7M
Cap. Flow
-$26.9M
Cap. Flow %
-11.58%
Top 10 Hldgs %
99.63%
Holding
15
New
–
Increased
–
Reduced
3
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$16.4M
2
STTK icon
Shattuck Labs
STTK
+$8.01M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$1.42M
4
RANI icon
Rani Therapeutics
RANI
+$640K
5
JBIO
Jade Biosciences
JBIO
+$402K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNLI icon
1
Denali Therapeutics
DNLI
$3.92B
$97.9M 42.13%
4,214,559
– –
HLVX
2
DELISTED
HilleVax
HLVX
$97.2M 41.85%
6,724,000
– –
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$676M
$16M 6.9%
1,557,063
-1,596,154
-51% -$16.4M
WVE icon
4
Wave Life Sciences
WVE
$1.18B
$6.72M 2.89%
1,346,892
– –
OVID icon
5
Ovid Therapeutics
OVID
$485M
$5.79M 2.49%
7,531,996
– –
TSBX
6
DELISTED
Turnstone Biologics
TSBX
$2.35M 1.01%
895,824
– –
STTK icon
7
Shattuck Labs
STTK
$679M
$1.99M 0.86%
515,619
-985,442
-66% -$8.01M
XLO icon
8
Xilio Therapeutics
XLO
$62.6M
$1.4M 0.6%
105,366
– –
EQ icon
9
Equillium
EQ
$134M
$1.26M 0.54%
1,824,977
– –
RANI icon
10
Rani Therapeutics
RANI
$88.5M
$818K 0.35%
215,172
-123,507
-36% -$640K
AMWL icon
11
American Well
AMWL
$217M
$505K 0.22%
77,733
– –
AKLI
12
DELISTED
Akili Inc
AKLI
$321K 0.14%
738,819
– –
LAB icon
13
Standard BioTools
LAB
$306M
$29.2K 0.01%
16,515
– –
JBIO
14
Jade Biosciences
JBIO
$1.33B
– –
-388
Closed -$402K
DAWN
15
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-85,840
Closed -$1.42M

Similar funds

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DADR
Dynamo Administracao de Recursos Rio De Janeiro, Brazil $18.5M AUM 37.41% 1-Year Est. Return
AVM
Avalon Ventures Management La Jolla, California $14.2M AUM 9.35% 1-Year Est. Return
RCMU
Rokos Capital Management (US) New York $14.2M AUM
PM
Pharo Management New York $18.7M AUM
SHM
Sagard Holdings Management Toronto, Ontario, Canada $20M AUM
SI
SQN Investors Menlo Park, California $12.8M AUM

Takeda Pharmaceutical Company's Q2 2024 Portfolio in Review

As of Q2 2024, Takeda Pharmaceutical Company held 15 positions worth $232M, down 20% from $289M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Takeda Pharmaceutical Company withdrew a net $26.9M in Q2 2024, closing 2 positions and reducing 3 holdings. Its most notable exit was Day One Biopharmaceuticals, an estimated $1.42M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Takeda Pharmaceutical Company's biggest Q2 2024 reduction was Phathom Pharmaceuticals, cutting an estimated $16.4M.
  • Takeda Pharmaceutical Company fully exited Day One Biopharmaceuticals in Q2 2024, selling an estimated $1.42M.
  • Takeda Pharmaceutical Company's ten largest holdings make up 100% of its $232M portfolio in Q2 2024.
  • Takeda Pharmaceutical Company opened 0 new positions and closed 2 in Q2 2024.
  • Takeda Pharmaceutical Company's portfolio value fell 20% quarter-over-quarter to $232M.

Based on Takeda Pharmaceutical Company's 13F filing for Q2 2024, filed 13 Feb 2025.